Sun Pharma Advanced Research Company Limited (NSE:SPARC)

Market Cap	48.63B
Revenue (ttm)	717.66M
Net Income (ttm)	-3.43B
Shares Out	324.52M
EPS (ttm)	-10.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	306,698
Average Volume	389,479
Open	150.00
Previous Close	150.54
Day's Range	148.85 - 153.99
52-Week Range	109.30 - 241.00
Beta	0.35
RSI	36.70
Earnings Date	Aug 4, 2025

About CTI BioPharma

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoria...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 316
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SPARC

Financial Performance

In 2024, NSE:SPARC's revenue was 717.66 million, a decrease of -5.00% compared to the previous year's 755.45 million. Losses were -3.43 billion, -11.55% less than in 2023.